Lipum receives 2.2 M€ grant from Horizon 2020

Horizon 2020, the EU framework program for research and development, will grant 2.2 million euros to Lipum’s ongoing development of a biological pharmaceutical for treatment of chronic inflammatory diseases.

Lipum has identified the novel target molecule Bile Salt-Stimulated Lipase (BSSL). Preclinical studies have very successfully verified the concept in several well-established models for autoimmune chronic inflammatory diseases, e.g. Rheumatoid Arthritis (RA). A candidate drug, an optimized monoclonal antibody, is now about to be validated and tested. Also a novel approach to get early proof of concept in man. In parallel production of the biological drug will be established for toxicological and clinical study during year 2020. The Horizon 2020 SME Instrument grant will speed up this development work to the benefit of patients, health care and society.

”We are indeed grateful for being selected by EU considering the tough competition. There is a significant unmet need for the treatment of these diseases and we have first-in-class potential”, says CEO Einar Pontén.

Dr Einar Pontén
+46 (0)70-578 34 95
Lipum aims for better quality of life for the millions suffering from chronic inflammatory diseases, including children. Distressed by pain, disability, and comorbidities many have to leave a normal working life in advance. We intend to increase their quality of life and decrease the considerable health care and societal costs.


About Us

Lipum is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores several other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant.